Eplontersen Trial Fails Primary Endpoint in ATTR-CM Study

Eplontersen failed to meet primary efficacy endpoint in the CARDIO-TTRansform trial for transthyretin-mediated amyloid cardiomyopathy.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.